No surgery after immunotherapy for MSI-H colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial is studying whether some people with a specific type of advanced colorectal cancer (MSI-H/dMMR) might be able to skip surgery after immunotherapy. Doctors will use a blood test (MRD monitoring) to track the cancer, and then decide whether to keep an eye on it or operate.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of colorectal cancer called MSI-H or dMMR (which means your tumor is likely to respond well to immunotherapy).
- Your cancer is locally advanced (stage II or III) – it has not spread to distant organs like the liver or lungs.
- You have not had any prior surgery, chemotherapy, radiation, or targeted therapy for this cancer.
- You do not have a serious autoimmune disease or an active uncontrolled infection like hepatitis B or C.
- You do not have a complete bowel blockage that hasn’t been treated.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a drug called an immune checkpoint inhibitor (PD-1 blocker) can help lower the risk of cancer returning after surgery. It is for people with a specific type of colorectal cancer (dMMR or MSI-H) that had certain high-risk features.
This trial tests a new immunotherapy drug (tislelizumab) given before surgery for people with stage II or III colorectal cancer that has a specific DNA repair problem (dMMR/MSI-High). The drug aims to shrink the tumor and improve treatment outcomes.
This trial tests a new immunotherapy drug (AK104) given before and after surgery for a specific type of colon cancer that is MSI-H or dMMR. The goal is to see if the drug helps shrink the tumor and prevent the cancer from coming back.
This trial tests whether using a simple blood test (ctDNA) can help guide treatment with immunotherapy drugs (PD-1 inhibitors) for people with a specific type of colon cancer (MSI-high/dMMR). The goal is to see if this approach can improve outcomes and reduce side effects compared to standard care.
This trial tests giving immunotherapy (a drug that boosts your immune system to fight cancer) with or without radiation before surgery for colorectal cancer that is MSI-High or dMMR. It aims to see if this approach can shrink tumors and improve outcomes.
This study tests whether an immunotherapy drug called tislelizumab can help prevent colon cancer from coming back after surgery. It is for people with a specific genetic feature (dMMR) in their tumor, which may make the treatment more effective.
Hear when a new Clinical Complete Response Rate With Negative MRD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.